Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial.


Body mass index (BMI) is a major risk factor for endometrial cancer incidence but its impact on post-treatment survival is unclear. We investigated the relationships of BMI (categorised using the WHO definitions) with clinico-pathological characteristics and outcome in women treated within the MRC ASTEC randomised trial, which provides data from patients… (More)
DOI: 10.1016/j.ejca.2011.10.003


8 Figures and Tables

Slides referencing similar topics